Mechanistically, the AR antagonist will bind the AR and joined by the linker, an E3 ubiquitin ligase will bind its ligand and tag the AR protein for degradation, thus reducing the abundance of the AR and dampening its activity, leading to repression of PCa progression [101], [102], [103]. Here, AR is linked to posterior cortical atrophy.